Asparcamp-UBF - instructions for use, doses, side effects, contraindications

Pharmacodynamics:Asparkam-UBF is a source of potassium and magnesium ions, regulates metabolic processes. The mechanism of action is presumably associated with the role of aspartate as a carrier of magnesium and potassium ions in the intracellular space and with the participation of aspartate in metabolic processes. Thus, Asparkam-UBF eliminates the imbalance of electrolytes, reduces the excitability and conductivity of the myocardium (moderate antiarrhythmic effect).

Pharmacokinetics:

Easily absorbed when ingested and relatively quickly excreted by the kidneys.

Indications:Asparkam-UBF is used in the complex therapy of chronic heart failure, ischemic heart disease, hypokalemia, cardiac rhythm disturbances (including myocardial infarction, cardiac glycoside overdose).

Contraindications:

Hypersensitivity to the drug, a violation of the exchange of amino acids, arterial hypotension, acute and chronic renal failure, hyperkalemia, hypermagnesia, violation of atrioventricular conduction (AV blockade I-III st.), severe myasthenia gravis, hemolysis, insufficiency of the adrenal cortex, the age of 18 years.

Pregnancy and lactation:

Caution is prescribed during pregnancy and lactation.

Dosing and Administration:

Asparkam-UBF is administered orally after meals.

Assign adults 1-2 tablets 3 times a day. The course of treatment is 3-4 weeks.

If necessary, repeat the course.

Side effects:

Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the epigastric region, (in patients with an anatomic gastritis or cholecystitis), atrioventricular blockade, paradoxical reaction (increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnia (reddening of the face, thirst, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions).

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Interaction:

Pharmacodynamic: a joint application with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and asystole.

The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter.

Due to the content of potassium ions, the undesirable effects of cardiac glycosides decrease.

Due to the content of magnesium ions reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium bezylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide)).

Calcitriol increases the concentration of magnesium ions in the blood plasma, calcium preparations reduce the effect of magnesium.

Pharmacokinetic: astringent and enveloping agents reduce the absorption of the drug in the gastrointestinal tract (a 3-hour interval between their intake must be observed).

Special instructions:

It is necessary to control the content of potassium ions in the blood plasma.

Effect on the ability to drive transp. cf. and fur:

Clinical studies to assess the effect of the drug on the ability to drive and perform work that requires increased attention, has not been carried out.

Form release / dosage:Pills.

Packaging:

For 10 tablets in a contour non-cellular package of paper with a polymer coating. For 10 tablets a contoured cellular package made of polyvinylchloride film and aluminum foil printed lacquered or paper with a polymer coating.

By 10, 20, 25, 30, 40, 50, 60 tablets in cans of polymeric.

Banks polymeric, or contour non-cellular packages, or contour mesh packages with an equal number of instructions for use are placed in a bag of polyethylene film or a cardboard box.

Each jar or 1, 2, 3, 5 contour squares, together with instructions for use, are placed in a cardboard pack.

Storage conditions:

In a dry place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date stated on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002050 / 01-2002

Date of registration:17.11.2008 / 28.03.2012

Expiration Date:Unlimited

The owner of the registration certificate:URALBIOFARM, OJSC URALBIOFARM, OJSC Russia

Manufacturer: & nbsp

URALBIOFARM, OJSC Russia

Information update date: & nbsp27.09.2017

Illustrated instructions

Instructions

Asparks-UBF (Asparcam-UBF)